Mutational landscape of PCNSL, according to EBV tissue and HIV serological status. (A) Each column in this plot represents an individual case (with mutation[s] in the displayed genes) of the final sequencing cohort (n = 79), across the 4 tissue subtypes: EBV⁻ HIV⁻ PCNSL, EBV⁻ HIV⁺ PCNSL, EBV⁺ HIV⁺ PCNSL, and EBV⁺ HIV⁻ PCNSL. Mutated genes constitute individual rows and are sorted according to their mutational frequencies of mutated cases as provided on the far right. Mutation types are color coded as indicated in the key; red* brain lymphoma TK cell-line, red** patients without PTLD/iatrogenic immunosuppression. (B) Stacked histograms show the percentage (percentages rounded to whole numbers) of cases with mutations in MYD88, CD79B, PIM1 by EBV-tissue and HIV serological status across the 3 main subtypes. Because EBV⁻ HIV⁺ PCNSL represented only 1 sequenced case, aggregate data are not shown. (C) Number of mutated genes observed using the targeted sequencing panel in EBV⁻ HIV⁻ PCNSL, EBV⁺ HIV⁺ PCNSL, and EBV⁺ HIV⁻ PCNSL, with P values for paired subtypes: *P ≤ .05; **P ≤ .01; ***P ≤ .001; ****P ≤ .0001.